Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Total Current Liabilities (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Total Current Liabilities readings, the most recent being $132.4 million for Q1 2026.

  • On a quarterly basis, Total Current Liabilities rose 18.58% to $132.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $132.4 million, a 18.58% increase, with the full-year FY2025 number at $147.2 million, up 21.94% from a year prior.
  • Total Current Liabilities hit $132.4 million in Q1 2026 for Catalyst Pharmaceuticals, down from $147.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $147.2 million in Q4 2025 to a low of $22.5 million in Q2 2022.
  • Median Total Current Liabilities over the past 5 years was $79.6 million (2024), compared with a mean of $83.6 million.
  • Biggest five-year swings in Total Current Liabilities: soared 147.23% in 2023 and later increased 18.58% in 2026.
  • Catalyst Pharmaceuticals' Total Current Liabilities stood at $57.6 million in 2022, then surged by 32.08% to $76.1 million in 2023, then soared by 58.66% to $120.7 million in 2024, then rose by 21.94% to $147.2 million in 2025, then fell by 10.03% to $132.4 million in 2026.
  • The last three reported values for Total Current Liabilities were $132.4 million (Q1 2026), $147.2 million (Q4 2025), and $128.7 million (Q3 2025) per Business Quant data.